Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles
- PMID: 19638575
- PMCID: PMC2755616
- DOI: 10.1158/0008-5472.CAN-09-1073
Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles
Abstract
Pathologic differentiation of tissue of origin in tumors found in the lung can be challenging, with differentiation of mesothelioma and lung adenocarcinoma emblematic of this problem. Indeed, proper classification is essential for determination of treatment regimen for these diseases, making accurate and early diagnosis critical. Here, we investigate the potential of epigenetic profiles of lung adenocarcinoma, mesothelioma, and nonmalignant pulmonary tissues (n = 285) as differentiation markers in an analysis of DNA methylation at 1413 autosomal CpG loci associated with 773 cancer-related genes. Using an unsupervised recursively partitioned mixture modeling technique for all samples, the derived methylation profile classes were significantly associated with sample type (P < 0.0001). In a similar analysis restricted to tumors, methylation profile classes significantly predicted tumor type (P < 0.0001). Random forests classification of CpG methylation of tumors--which splits the data into training and test sets--accurately differentiated mesothelioma from lung adenocarcinoma over 99% of the time (P < 0.0001). In a locus-by-locus comparison of CpG methylation between tumor types, 1266 CpG loci had significantly different methylation between tumors following correction for multiple comparisons (Q < 0.05); 61% had higher methylation in adenocarcinoma. Using the CpG loci with significant differential methylation in a pathway analysis revealed significant enrichment of methylated gene-loci in Cell Cycle Regulation, DNA Damage Response, PTEN Signaling, and Apoptosis Signaling pathways in lung adenocarcinoma when compared with mesothelioma. Methylation profile-based differentiation of lung adenocarcinoma and mesothelioma is highly accurate, informs on the distinct etiologies of these diseases, and holds promise for clinical application.
Figures



Similar articles
-
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.Cancer Res. 2009 Dec 1;69(23):9073-82. doi: 10.1158/0008-5472.CAN-09-1595. Epub 2009 Nov 3. Cancer Res. 2009. PMID: 19887624
-
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome.Cancer Res. 2009 Jan 1;69(1):227-34. doi: 10.1158/0008-5472.CAN-08-2586. Cancer Res. 2009. PMID: 19118007 Free PMC article.
-
Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases.Clin Epigenetics. 2024 Dec 3;16(1):176. doi: 10.1186/s13148-024-01790-z. Clin Epigenetics. 2024. PMID: 39627815 Free PMC article.
-
Applications of array-CGH for lung cancer.Methods Mol Biol. 2013;973:297-324. doi: 10.1007/978-1-62703-281-0_19. Methods Mol Biol. 2013. PMID: 23412798 Review.
-
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.Eur J Cardiothorac Surg. 2014 Oct;46(4):602-6. doi: 10.1093/ejcts/ezu048. Epub 2014 Mar 12. Eur J Cardiothorac Surg. 2014. PMID: 24623168 Free PMC article. Review.
Cited by
-
Non-neoplastic and neoplastic pleural endpoints following fiber exposure.J Toxicol Environ Health B Crit Rev. 2011;14(1-4):153-78. doi: 10.1080/10937404.2011.556049. J Toxicol Environ Health B Crit Rev. 2011. PMID: 21534088 Free PMC article. Review.
-
Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.Oncotarget. 2016 Jul 12;7(28):43461-43474. doi: 10.18632/oncotarget.9494. Oncotarget. 2016. PMID: 27223257 Free PMC article.
-
Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.Epigenetics. 2011 Jun;6(6):703-9. doi: 10.4161/epi.6.6.16158. Epub 2011 Jun 1. Epigenetics. 2011. PMID: 21610323 Free PMC article.
-
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.J Mol Diagn. 2010 Nov;12(6):771-9. doi: 10.2353/jmoldx.2010.090169. Epub 2010 Sep 23. J Mol Diagn. 2010. PMID: 20864637 Free PMC article.
-
DNA methylation determines nucleosome occupancy in the 5'-CpG islands of tumor suppressor genes.Oncogene. 2013 Nov 21;32(47):5421-8. doi: 10.1038/onc.2013.162. Epub 2013 May 20. Oncogene. 2013. PMID: 23686312 Free PMC article.
References
-
- Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129–35. - PubMed
-
- Robinson BW, Lake RA. Advances in malignant mesothelioma. The New England journal of medicine. 2005;353:1591–603. - PubMed
-
- Nguyen GK, Akin MR, Villanueva RR, Slatnik J. Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy. Diagn Cytopathol. 1999;21:253–9. - PubMed
-
- Antman KH. Current concepts: malignant mesothelioma. The New England journal of medicine. 1980;303:200–2. - PubMed
-
- Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications. Thorac Surg Clin. 2004;14:523–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01CA126831/CA/NCI NIH HHS/United States
- R01 ES006717/ES/NIEHS NIH HHS/United States
- P30ES00002/ES/NIEHS NIH HHS/United States
- P42ES05947/ES/NIEHS NIH HHS/United States
- P42 ES005947/ES/NIEHS NIH HHS/United States
- P50 CA097257/CA/NCI NIH HHS/United States
- T32ES007155/ES/NIEHS NIH HHS/United States
- R01CA105274/CA/NCI NIH HHS/United States
- R01 CA126939/CA/NCI NIH HHS/United States
- T32 ES007155/ES/NIEHS NIH HHS/United States
- R01ES006717/ES/NIEHS NIH HHS/United States
- P30 ES000002/ES/NIEHS NIH HHS/United States
- ES/CA06409/CA/NCI NIH HHS/United States
- R01 CA126831/CA/NCI NIH HHS/United States
- R01 CA105274/CA/NCI NIH HHS/United States
- R01 CA078609/CA/NCI NIH HHS/United States
- P50CA097257/CA/NCI NIH HHS/United States
- R01CA126939/CA/NCI NIH HHS/United States
- R01 CA100679/CA/NCI NIH HHS/United States
- R01CA52689/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials